Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

A legfontosabb adatok

Ki végzi
Phathom Pharmaceuticals, Inc.
Hol
Atlanta, Dayton, El Paso, Frisco, Gresham, Hollywood, Indianapolis, Little Rock, Marrero, Mobile, Pensacola, Tampa és The Bronx (Egyesült Államok)Mind a 13 helyszín megnézése
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
22 fő vett részt
Kezdés
2023. nov. 1.
Befejezés
2024. ápr. 29.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Vonoprazan
A regiszteradat frissítve
2024. december 19.

Ki vehet részt

Életkor
6 év – 11 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • The participant has a body weight within the 5th through 95th percentile by age, inclusive, as determined by the National Center for Health Statistics
  • The participant must have a diagnosis of GERD prior to randomization and medical history of signs or symptoms of GERD for at least 3 months prior to screening, based on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, pH or endoscopy). Notes in the medical records and/or other source documents, such as prior endoscopies, can be used to support the diagnosis and will be recorded in the electronic case report form (eCRF)
  • The participant has at least one moderate GERD symptom based on the GERD Symptom Assessment Investigator scale performed at screening
  • The participant must be able to swallow study drug tablet with water
  • Parent or legal guardian (ie, legally authorized representative [LAR]) is willing and able to complete the informed consent process and participants are able to comply with study procedures and visit schedule
  • Female participants who have experienced menarche must have a negative pregnancy test and will be counseled on pregnancy avoidance

Ki nem vehet részt

  • The participant has used prescription or non-prescription proton pump inhibitors (PPIs) or histamine-2 receptor antagonist (H2RAs) within 7 days prior to randomization or requires use during the Treatment Period
  • The participant has used sucralfate, or antacids within 1 day prior to randomization or requires their use during the Treatment Period
  • The participant has received other agents affecting digestive organs, including muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study
  • The participant has received atazanavir sulfate or rilpivirine hydrochloride from 5 days prior to Day 1 or requires their use during the course of the study
  • The participant has received any investigational compound (including vonoprazan) within 30 days prior to the start of the Screening Period
  • The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Period
  • The participant has undergone prior gastrointestinal surgeries
  • The participant has used any prescription or over-the-counter medications (including herbal or nutritional supplements), other than those already excluded in criteria 1 to 5 above, within 14 days before the first dose of study drug or throughout the study. That is, unless the medication(s) is permitted by the sponsor following a review of available data which confirms concomitant administration of the medication is unlikely to affect either the safety of the participant or the pharmacokinetics of vonoprazan
  • The participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study
  • The participant has positive results at screening for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus (HCV)
  • The participant has severe renal impairment (estimated glomerular filtration rate < 30 mL/min)
  • The participant has moderate to severe hepatic impairment (Child-Pugh Class B and Child-Pugh Class C)
  • The participant has any abnormal laboratory test values that are considered clinically significant in the opinion of the investigator during the Screening Period
  • The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropylcellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, and titanium dioxide, or red or yellow ferric oxide)
  • The participant has any of the following abnormal laboratory test values at the start of the Screening Period:; Creatinine levels: >0.8 mg/dL (>70 μmol/L); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × the upper limit of normal (ULN) or total bilirubin >2 × ULN (except participants with Gilbert Syndrome)
  • The participant is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or participant may have consented under duress
  • In the opinion of the investigator, the participant is not suitable for entry into the study

Helyszínek itt: Egyesült Államok

  • Children's Center for Digestive Health Care, LLCAtlanta, Egyesült Államok
  • Primed Clinical ResearchDayton, Egyesült Államok
  • Maspons Pediatric GastroEl Paso, Egyesült Államok
  • Stryde Research - NxT Step PediatricsFrisco, Egyesült Államok
  • Cyn3rgy ResearchGresham, Egyesült Államok
  • Med Research Associates, IncHollywood, Egyesült Államok
  • Riley Hospital for Children at IU HealthIndianapolis, Egyesült Államok
  • Preferred Research Partners, IncLittle Rock, Egyesült Államok
  • Tandem Clinical Research GI, LLCMarrero, Egyesült Államok
  • Strada Patient Care CenterMobile, Egyesült Államok
  • Avanza Medical Research CenterPensacola, Egyesült Államok
  • International Center for ResearchTampa, Egyesült Államok
  • Advantage Clinical TrialsThe Bronx, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).

A vizsgálat 2 csoportja

  • Vonoprazan 10mgA vizsgált kezelés

    Participants will receive vonoprazan 10mg QD for 14 days.

    Kezelés: Vonoprazan

  • Vonoprazan 20mgA vizsgált kezelés

    Participants will receive vonoprazan 20mg QD for 14 days.

    Kezelés: Vonoprazan

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease
A regiszteradat frissítve
2024. december 19.